logo
Twitter
Discord
Email
logo
Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc

NASDAQ•CNTA
CEO: Dr. Saurabh Saha M.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-05-28
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Contact Information
1 Ashley Road, 3rd Floor, Altrincham, WA14 2DT, United Kingdom
N/A
www.centessa.com
Market Cap
$2.98B
P/E (TTM)
-12.3
38.2
Dividend Yield
--
52W High
$30.58
52W Low
$9.60
52W Range
60%
Rank73Top 99.9%
0.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 0.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.41+10.81%
4-Quarter Trend

FCF

-$58.55M+173.29%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Genmab License Revenue Recognized Recognized $15.0M upfront revenue from Genmab License Agreement in Q1 2025, boosting nine-month revenue.
R&D Investment Ramps Up R&D expenses increased $33.3M to $117.7M for nine months, focusing on OX2R agonist pipeline advancement.
Cash Position Maintained Cash, equivalents, and investments totaled $349.0M as of September 30, 2025, funding operations into mid-2027.
ORX142 Clinical Advancement Initiated Phase 1 FIH clinical trial for ORX142, the second OX2R agonist candidate, following IND clearance in June 2025.

Risk Factors

Net Loss Widens Nine-month net loss increased to $(131.4M) from $(124.4M) due to higher R&D costs and program termination expenses.
Operating Cash Usage Rises Net cash used in operating activities rose to $(138.0M) for nine months, reflecting $28.3M in program termination payments made.
Development Success Uncertain Product candidates face high failure rates; success hinges on demonstrating safety and efficacy in ongoing clinical trials.
Need for Capital Substantial additional capital required to fund ongoing operations and expected increased expenses into mid-2027.

Outlook

ORX750 Dose Selection Planned Expect Phase 2a study results to enable dose selection for the registrational program targeted for the first quarter of 2026.
Pipeline Candidates Advancing Planning patient studies for ORX142 in Q1 2026; ORX489 is currently in IND-enabling studies.
Future Financing Anticipated Anticipate needing substantial additional funding to support ongoing development activities and expected commercialization expenses.
Prioritizing OX2R Franchise Strategic decision made to prioritize capital towards the development of the growing OX2R agonist franchise.

Peer Comparison

Revenue (TTM)

Apellis Pharmaceuticals, Inc.APLS
$1.02B
+42.1%
Legend Biotech CorporationLEGN
$908.96M
+74.7%
Ultragenyx Pharmaceutical Inc.RARE
$630.60M
+20.6%

Gross Margin (Latest Quarter)

Apellis Pharmaceuticals, Inc.APLS
94.7%
+11.7pp
uniQure N.V.QURE
89.2%
+33.9pp
Ultragenyx Pharmaceutical Inc.RARE
82.5%
-2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CDTX$5.61B-18.6-60.1%0.4%
IMVT$4.61B-9.8-84.9%0.0%
SRRK$4.59B-14.5-122.0%26.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 23, 2026
|
EPS:-$0.38
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.41+10.8%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.38-5.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $15.00M+0.0%
    |
    EPS: $-0.20-47.4%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 24, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-2.06-31.2%
    N/A

  • Form 10-Q/A - Q3 2024

    Period End: Sep 30, 2024|Filed: Feb 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.37-7.5%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|Refer to amended data

  • Form 10-Q/A - Q2 2024

    Period End: Jun 30, 2024|Filed: Oct 18, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.40+53.8%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|Refer to amended data